Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Globe Newswire

03:11 EST 19th January 2019 | BioPortfolio

Here are the most relevant search results for "Globe Newswire" found in our extensive news archives from over 250 global news sources.

More Information about Globe Newswire on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Globe Newswire for you to read. Along with our medical data and news we also list Globe Newswire Clinical Trials, which are updated daily. BioPortfolio also has a large database of Globe Newswire Companies for you to search.

Showing News Articles 1–25 of 21,000+ from Globe Newswire

Thursday 17th January 2019

Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering Priced At-the-Market

HOUSTON, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (Bio-Path),  a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into definitive agreements with several healthcare focused institutional investors for the issuance ...

Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression

– Tipifarnib is a CXCL12 pathway inhibitor that may provide clinical benefit in subsets of patients with pancreatic cancer – – Analysis of a previously conducted, randomized Phase 3 trial reveals patients with lymph node or liver metastases and those with no abdominal pain appear more likely to benefit from tipifarnib – – Low KRAS mutant allele frequency (~ 30% of pancreatic patient ...

InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmissions at LINC, 22nd to the 25th January 2019, in Leipzig, Germany

TEL AVIV, Israel, Jan. 18, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Carotid Embolic Prevention System (EPS) will be featured in two live case transmissions at the Leipzig Interventional Course (LINC) 2019 to be held from January 22nd to ...

Aleafia Health Completes Strategic Investment in Australia’s CannaPacific Pty Limited

Global Expansion Underway with 10% Equity Investment in Licensed Cannabis Cultivator CannaPacific among Australia’s only Federally Licensed Cultivators with projected 108,000 sq. ft. Greenhouse TORONTO, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSXV: ALEF: OTCQX: ALEAF, FRA: ARAH) (“Aleafia Health”) or the (“Company”) is announcing its global expansion with the closing o...

Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

HOUSTON, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announces a 1-for-20 reverse stock split of its issued and outstanding common stock, which was previously approved by the Company’s Board of Directo...

CTD Announces Partnership with United BioSource LLC (UBC) to support the Extension Protocol for its Phase I Clinical Trial in the United States

ALACHUA, Fla., Jan. 18, 2019 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced its newest partner in support of its US clinical program, United BioSource LLC (UBC). UBC provides pharmaceutical and home nursing services in support of clinical ...

TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study of Patients with Advanced Pancreatic Cancer

68% of evaluable patients with actively progressing end-stage pancreatic cancer receiving monotherapy SM-88 remain alive with a median follow-up of 4.3 months (median 5.8 months from completing last therapy)Of 14 patients receiving SM-88 as third-line therapy, 79% remain alive after a median follow-up of 4.7 months; survival was more than double when compared to the median expected survival of th...

Amicus Therapeutics Announces Presentations and Posters at 15th Annual WORLDSymposium™ 2019

CRANBURY, N.J., Jan. 18, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced that four oral presentations and eight posters highlighting its development programs for Lysosomal Storage Disorders will be included at the 15th Annual WORLD

AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis

CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) a Phase 2 clinical-stage gene therapy company, today announced that its investigational gene therapy candidate for cystinosis, AVR-RD-04, is cleared to begin a Phase 1/2 clinical trial

Correction: Managers’ transactions

Company announcement no.02/2019 Correction: Purchase of shares in Chr. Hansen Holding A/S For further information, please contact: Martin Riise, Head of Investor Relations, Tel: +45 53 39 22 50 Camilla Lercke, Head of Media Relations, Tel: +45 53 39 23 84 About Chr. Hansen Chr. Hansen is a leading global biosci...

Immunomedics Receives Complete Response Letter From FDA for Sacituzumab Govitecan Biologics License Application

MORRIS PLAINS, N.J., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) seeking accelerated app...

Wednesday 16th January 2019

Lexicon Pharmaceuticals to Host Conference Call and Webcast on January 17, 2019 to Discuss Outcome of FDA Advisory Committee Meeting for Sotagliflozin in Type 1 Diabetes

THE WOODLANDS, Texas, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that management will conduct a conference call and live webcast on Thursday, January 17, 2019, at 7:00 p.m. EST (6:00 p.m. CST) to discuss the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting in connectio...

FDA Advisory Committee Votes on Zynquista™ (sotagliflozin) as Treatment for Adults With Type 1 Diabetes

PARIS and THE WOODLANDS, Texas, Jan. 17, 2019 (GLOBE NEWSWIRE) -- The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) today voted eight to eight on the question of whether the overall benefits of Zynquista™* (sotagliflozin) outweighed the risks to support approval. Sotagliflozin is an investigational oral dual SGLT1 and SGLT2 inhibitor unde...

Alder BioPharmaceuticals® Appoints Paul Streck, M.D. Chief Medical Officer

BOTHELL, Wash., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced the appointment of Paul Streck, M.D., as chief medical officer (CMO), effective January 21, 2019.  He will report to Bob Azelby, Alder’s president and chief executive offi...

Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series E Convertible Preferred Stock in underwritten public offerings. There can be no assurance as to whether or when the proposed offerings may be completed, or as t...

Bio-Path Holdings, Inc. Announces Closing of Public Offering of Common Stock

HOUSTON, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing and funding of its previously announced underwritten public offering of 8,592,308 shares of its common stock a...

Updated Clinical Data from Combination of Margetuximab and Pembrolizumab in Gastric Cancer Presented at 2019 ASCO Gastrointestinal Cancers Symposium

32.7% Objective response rate in HER2+ IHC 3+ second-line gastric cancer patientsWell tolerated in dose escalation and expansion cohorts ROCKVILLE, MD, Jan. 17, 2019 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cance...

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; January 17, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish Capital Markets Act that BlackRock, Inc. has informed us that, as of October 11, 2018, BlackRock, Inc. has decreased their total ownership (indirectly owned shares and financial instruments) in Gen...

Taconic Biosciences’ Animals Complete Most Recent Mission to the International Space Station

RENSSELAER, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces the completion of a recent mission to the International Space Station.  This project represents a collaboration between the International Space Station (ISS) National Lab, National Aeronautics and Space Administration (NASA), Bioserve ...

CORRECTING and REPLACING -- Progressive Care Releases Open Letter to Shareholders

MIAMI, Jan. 17, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Progressive Care Inc. (OTCQB:RXMD) please note that in the heading of the bulleted section under "Outlook" the year has been changed from 2018 to 2019 ("The following are our strategic goals for 2019"). The corrected release follows: Progressive Care Releases Open Letter to Shareholders Open...

Pain Therapeutics Announces Academic Collaboration with The University of Texas at Austin

AUSTIN, Texas, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a drug development company, announced today it has entered into an academic collaboration with UT Austin in support of a product candidate aimed at pain management, abuse and addiction. The collaboration brings together the Company and UT Austin’s respective scientific expertise and capabilities, with a f...

Kane Biotech Positions DispersinB® for Wound Care treatment in United States: Applies for U.S. Army Medical Research Funding and renews commitment to Rutgers University

WINNIPEG, Manitoba, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), announced today the kick-off of their new human health strategy. Efforts will be focused on development of a wound care hydrogel containing Kane’s patented enzyme DispersinB®. Marc Edwards, Chief Executive Officer of Kane Biotech, stated, “I belie...

Abattis Removed From BCSC Temporary Order

VANCOUVER, British Columbia, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that the temporary order from the British Columbia Securities Commission (“BCSC”), issued on November 26, 2018 (the “Order”), has not been extended against Abattis. “Abattis is very happy with the BCSC’s decision...

Vaccinex, Inc. Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503 (Pepinemab) in Huntington’s Disease (the “SIGNAL Trial”) at Cambridge Healthtech Institute’s 18th Annual PepTalk

ROCHESTER, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announces vice president of preclinical research, Elizabeth ...

FSD Pharma & Canntab Rank Among the Top 2018 Cannabis Stocks -- CFN Media

SEATTLE, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc’s. (CSE: HUGE) (OTC: FSDDF) (FSE: 0K9) & Canntab Therapeutics Ltd’s. (CSE: PILL) (TBF1.F) performance in 2018. The cannabis i...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks